Amgen (WBO:AMGN) Change In Receivables : €-941 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Amgen Change In Receivables?

Amgen's change in receivables for the quarter that ended in Dec. 2023 was €-397 Mil. It means Amgen's Accounts Receivable increased by €397 Mil from Sep. 2023 to Dec. 2023 .

Amgen's change in receivables for the fiscal year that ended in Dec. 2023 was €-931 Mil. It means Amgen's Accounts Receivable increased by €931 Mil from Dec. 2022 to Dec. 2023 .

Amgen's Accounts Receivable for the quarter that ended in Dec. 2023 was €6,665 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Amgen's Days Sales Outstanding for the three months ended in Dec. 2023 was 80.92.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Amgen's liquidation value for the three months ended in Dec. 2023 was €-63,977 Mil.

Amgen Change In Receivables Historical Data

The historical data trend for Amgen's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Change In Receivables Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-453.60

-350.99

-379.67

-704.22

-930.76

Amgen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-169.92	-134.50	-88.61	-320.45	-397.06

Amgen Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-941 Mil.

Amgen (WBO:AMGN) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Amgen's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	6664.756	/	7515.732	*	91
=	80.92

2. In Ben Graham's calculation of liquidation value, Amgen's accounts receivable are only considered to be worth 75% of book value:

Amgen's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	10035.648	-	83375.474	+	0.75 * 6664.756	+	0.5 * 8728.006
=	-63,977

Amgen Change In Receivables Related Terms

Thank you for viewing the detailed overview of Amgen's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (WBO:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (WBO:AMGN) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN34:Brazil AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.